Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2) for early detection and laboratory diagnosis

Molecular Genetics and Metabolism

119, 160-167

DOI: 10.1016/j.ymgme.2016.07.011

Citation Report

#	Article	IF	Citations
1	Management Strategies for CLN2 Disease. Pediatric Neurology, 2017, 69, 102-112.	1.0	80
2	Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease. Epilepsia, 2017, 58, 1380-1388.	2.6	50
3	Translating preclinical models of neuronal ceroid lipofuscinosis: progress and prospects. Expert Opinion on Orphan Drugs, 2017, 5, 727-740.	0.5	6
4	Gene Therapy Approaches to Treat the Neurodegeneration and Visual Failure in Neuronal Ceroid Lipofuscinoses. Advances in Experimental Medicine and Biology, 2018, 1074, 91-99.	0.8	14
5	Evolution and course of early life developmental encephalopathic epilepsies: Focus on Lennoxâ€Gastaut syndrome. Epilepsia, 2018, 59, 2096-2105.	2.6	35
6	Metabolic ataxias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 155, 117-127.	1.0	5
7	Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. Human Mutation, 2019, 40, 1924-1938.	1.1	46
8	Advances in the treatment of neuronal ceroid lipofuscinosis. Expert Opinion on Orphan Drugs, 2019, 7, 473-500.	0.5	20
9	Perampanel attenuates myoclonus in a patient with neuronal ceroid lipofuscinoses type 2 disease. Brain and Development, 2019, 41, 817-819.	0.6	8
10	Global Brain Transcriptome Analysis of a Tpp1 Neuronal Ceroid Lipofuscinoses Mouse Model. ASN Neuro, 2019, 11, 175909141984339.	1.5	13
11	Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease. Clinica Chimica Acta, 2019, 492, 69-71.	0.5	14
12	Therapeutic landscape for Batten disease: current treatments and future prospects. Nature Reviews Neurology, 2019, 15, 161-178.	4.9	127
13	Overview of advances in educational and social supports for young persons with NCL disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165480.	1.8	2
14	Autism, Epilepsy, and Neuroregression: Photosensitivity on Electroencephalography Solved the Riddle. Clinical EEG and Neuroscience, 2020, 51, 399-402.	0.9	6
15	Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2. Journal of Child Neurology, 2020, 35, 348-353.	0.7	20
16	Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. Science Translational Medicine, 2020, 12, .	5.8	35
17	Cerliponase alfa for CLN2 disease, a promising therapy. Expert Opinion on Orphan Drugs, 2020, 8, 445-454.	0.5	1
18	The improvement in diagnosis and epilepsy managing in children with progressive myoclonus epilepsy during the last decade â€" A tertiary center experience in cohort of 51 patients. Epilepsy and Behavior, 2020, 113, 107456.	0.9	5

#	Article	IF	Citations
19	Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics. Pediatric Neurology, 2020, 110, 64-70.	1.0	12
20	A multimodal approach to identify clinically relevant biomarkers to comprehensively monitor disease progression in a mouse model of pediatric neurodegenerative disease. Progress in Neurobiology, 2020, 189, 101789.	2.8	9
21	Neuronal ceroid lipofuscinosis in the Russian population: Two novel mutations and the prevalence of heterozygous carriers. Molecular Genetics & Genomic Medicine, 2020, 8, e1228.	0.6	9
22	Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the â€˜beyond epilepsyâ€™ project. Italian Journal of Pediatrics, 2020, 46, 92.	1.0	17
23	Drug Treatment of Progressive Myoclonic Epilepsy. Paediatric Drugs, 2020, 22, 149-164.	1.3	12
24	Neuronal ceroid lipofuscinosis type 2: an Australian case series. Journal of Paediatrics and Child Health, 2020, 56, 1210-1218.	0.4	19
25	Diagnosis of late-infantile neuronal ceroid lipofuscinosis using dried blood spot-based assay for TPPI enzyme activity. Clinica Chimica Acta, 2020, 507, 62-68.	0.5	1
26	Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy . Therapeutics and Clinical Risk Management, 2020, Volume 16, 213-222.	0.9	34
27	Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy. Drugs, 2021, 81, 101-123.	4.9	35
28	Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort. European Journal of Paediatric Neurology, 2021, 30, 17-21.	0.7	13
29	â€œAtypicalâ€•Phenotypes of Neuronal Ceroid Lipofuscinosis: The Argentine Experience in the Genomic Era. Journal of Inborn Errors of Metabolism and Screening, 0, 9, .	0.3	1
30	Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies. Expert Review of Neurotherapeutics, 2021, 21, 1275-1282.	1.4	5
31	Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet Journal of Rare Diseases, 2021, 16, 185.	1.2	17
32	â€œReal world effectiveness of cerliponase alfa in classical and atypical patients. A case seriesâ€• Molecular Genetics and Metabolism Reports, 2021, 27, 100718.	0.4	7
33	Ocular Manifestations of Neuronal Ceroid Lipofuscinoses. Seminars in Ophthalmology, 2021, 36, 582-595.	0.8	2
34	Unraveling neuronal ceroid lipofuscinosis type 2 (CLN2) disease: A tertiary center experience for determinants of diagnostic delay. European Journal of Paediatric Neurology, 2021, 33, 94-98.	0.7	4
35	An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy. Eye, 2021, 35, 2438-2448.	1.1	6
36	A diagnostic confidence scheme for <scp>CLN3</scp> disease. Journal of Inherited Metabolic Disease, 2021, 44, 1453-1462.	1.7	3

#	Article	IF	Citations
38	Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world. Journal of Paediatrics and Child Health, 2021, 57, 519-525.	0.4	15
39	New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System. Current Pharmaceutical Design, 2019, 25, 1933-1950.	0.9	11
40	Patient-Derived Induced Pluripotent Stem Cell Models for Phenotypic Screening in the Neuronal Ceroid Lipofuscinoses. Molecules, 2021, 26, 6235.	1.7	4
41	Praise for child neuropsychiatry. Turk Pediatri Arsivi, 2019, 55, 453-454.	0.9	0
42	Physiotherapy for Children with CLN2 Disease. Journal of Inborn Errors of Metabolism and Screening, 0, 7, .	0.3	0
43	A Case with Neonatal-onset Type 2 Neuronal Ceroid Lipofuscinosis: A Novel Mutation. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP, 2020, 30, 543-544.	0.2	2
44	A Case Report on the Challenging Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2). Journal of Inborn Errors of Metabolism and Screening, 0, 8, .	0.3	1
45	Is it autism? Some suggestions for pediatricians. Turk Pediatri Arsivi, 2020, 55, 229-235.	0.9	7
46	Position of Experts Regarding Follow-Up of Patients with Neuronal Ceroid Lipofuscinosis-2 Disease in Latin America. Journal of Inborn Errors of Metabolism and Screening, 0, 8, .	0.3	2
47	Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression. Journal of Neuroinflammation, 2021, 18, 262.	3.1	5
48	Neurophysiological Findings in Neuronal Ceroid Lipofuscinoses. Frontiers in Neurology, 2022, 13, 845877.	1.1	7
49	The LINCE Project: A Pathway for Diagnosing NCL2 Disease. Frontiers in Pediatrics, 2022, 10, 876688.	0.9	1
51	Value of genetic testing for pediatric epilepsy: Driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease. Epilepsia, 2022, 63, .	2.6	6
52	Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis. International Journal of Molecular Sciences, 2022, 23, 5729.	1.8	7
53	Neuronal Ceroid Lipofuscinosis Type 2: A Case Series from Argentina. Journal of Inborn Errors of Metabolism and Screening, 0, 10, .	0.3	0
54	Provoked seizures at the onset of progressive disease contribute to diagnosis delay - A tertiary center experience in a cohort of 22 children with CLN2. European Journal of Paediatric Neurology, 2022, 40, 1-4.	0.7	1
55	Role of Electroencephalogram (EEG) and Magnetic Resonance Imaging (MRI) Findings in Early Recognition and Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 Disease. Journal of Child Neurology, 2022, 37, 984-991.	0.7	1
57	Buffy Coat Score as a Biomarker of Treatment Response in Neuronal Ceroid Lipofuscinosis Type 2. Brain Sciences, 2023, 13, 209.	1.1	2

#	Article	IF	Citations
58	Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease. Experimental Neurology, 2023, 363, 114381.	2.0	0
59	The conserved cellular roles of CLN proteins: Novel insights from Dictyostelium discoideum. European Journal of Cell Biology, 2023, 102, 151305.	1.6	1
61	Optimizing Therapy of Seizures in Children and Adolescents with Developmental Disabilities. , 2023, , 631-653.		0
62	Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2). Expert Review of Pharmacoeconomics and Outcomes Research, 2023, 23, 561-570.	0.7	1
70	Molecular analysis in exons 1 and 2 of the tripeptidyl peptidase 1 (TPP1) gene on patients with neuronal ceroid lipofuscinosis type 2 (CLN2) in Indonesia. AIP Conference Proceedings, 2024, , .	0.3	0